Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 38

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 38
---
 will receive
80% of license income. Payments of license income shall be paid in U.S. dollars quarterly each year. On February 19, 2021, we entered
into an agreement with FSURF, subsequently amended on February 15, 2023, and effective on March 24, 2025, that collectively granted an
option, effective through March 23, 2026, to us to license methods for purifying castanospermine and its use for the treatment of COVID-19.
On August 19, 2021, we entered into an agreement with FSURF, subsequently amended on February 15, 2023, and effective on March 24, 2025,
that collectively granted an option, effective through March 23, 2026, to us to license a patent relating to the use of alpha glucosidase
inhibitors (including castanospermine and Celgosivir) for treatment of Zika infections.

Ending
upon July 12, 2033 or the conversion or redemption in full of all of the shares of Series A Preferred Stock owned by Knight, we will
pay Knight a royalty equal to 3.5% of our net sales, where “net sales” has the same meaning as in our license agreement with
the U.S. Army for Tafenoquine. Due to the success of the qualified IPO, at the end of the quarter and each quarter thereafter the
royalty will be calculated, and payment will be made within fifteen days.

17

Sales
and Marketing

In 2025, we plan to “relaunch” Arakoda
for malaria prevention in the United States as described in the “Strategy” section.

In
2023, we began to see named-patient sales in Europe, without any adjustments to pricing, triggering the purchase of another partial lot
of Arakoda by our European distributor. Sales volume has increased in Australia in response to repricing of Kodatef by our local distributor
to be more competitive with atovaquone-proguanil.

Manufacturing

We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates.

Australian Research Tax Credit and Overseas Finding Process

Under Section 27 of the Industry Research and
Development Act 198638, the Australian government offers a research tax credit of 43.5% on registered research and development
activities executed in Australia by eligible Australian domiciled entities. Companies